7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
Learn how Mounjaro (tirzepatide) affects eGFR and kidney function. Review clinical trial data from SURPASS and SURMOUNT programs, monitoring timelines, and what eGFR changes mean for patients on tirzepatide.
Tirzepatide (Mounjaro) can lower AST in many patients by reducing hepatic steatosis, but transient AST elevations also occur. Learn the clinical data, monitoring schedule, and what your numbers mean.
Tirzepatide (Mounjaro) is expected to lower CGM glucose and raise time in range within weeks of dose escalation. What is established from trial evidence, what needs primary-source verification, and how to adjust CGM monitoring during titration.
Tirzepatide (Mounjaro) lowers fasting plasma glucose by 43 to 65 mg/dL in type 2 diabetes. Learn the mechanism, timeline, trial data from SURPASS-1 through SURPASS-5, and monitoring recommendations.
Tirzepatide (Mounjaro) lowers fasting triglycerides by 19 to 25% in clinical trials. Learn the mechanism, timeline, monitoring schedule, and what the SURPASS data show.
Tirzepatide (Mounjaro) can shift multiple CMP markers including fasting glucose, ALT, AST, creatinine, and electrolytes. This article reviews the direction and general magnitude of those changes from published SURPASS trial data, and flags where exact numbers need verification against the primary source.
Tirzepatide (Mounjaro) measurably shifts triglycerides, LDL cholesterol, and HDL. Learn the magnitude, timing, mechanism, and when to recheck your lipid panel on treatment.